A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD | Zendy

Kristen L. Nowak | Zendy; Rahul Kakkar | Zendy; Matt Devalaraja | Zendy; Larry Lo | Zendy; Wansu Park | Zendy; Jogarao Gobburu | Zendy; Douglas Kling | Zendy; Michael Davidson | Zendy; Michel Chonchol | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD

Author(s) -

Kristen L. Nowak,

Rahul Kakkar,

Matt Devalaraja,

Larry Lo,

Wansu Park,

Jogarao Gobburu,

Douglas Kling,

Michael Davidson,

Michel Chonchol

Publication year - 2020

Publication title -

kidney360

Language(s) - English

Resource type - Journals

ISSN - 2641-7650

DOI - 10.34067/kid.0005862020

Subject(s) - medicine , placebo , adverse effect , cohort , population , inflammation , pharmacokinetics , c reactive protein , pharmacodynamics , gastroenterology , systemic inflammation , randomized controlled trial , pathology , alternative medicine , environmental health

Chronic systemic inflammation is highly prevalent in patients with CKD (measured as an elevated high-sensitivity C-reactive protein, hsCRP) and independently associated with cardiovascular events and all-cause mortality. An IL-6 blocker to suppress inflammation represents a potential novel paradigm to reduce cardiovascular risk in CKD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research